Target
MAP/microtubule affinity-regulating kinase 3
Ligand
BDBM50536675
Substrate
n/a
Meas. Tech.
ChEMBL_1934024 (CHEMBL4479676)
IC50
1.000000±n/a nM
Citation
 Sloman, DLNoucti, NAltman, MDChen, DMislak, ACSzewczak, AHayashi, MWarren, LDellovade, TWu, ZMarcus, JWalker, DSu, HPEdavettal, SCMunshi, SHutton, MNuthall, HStanton, MG Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties. Bioorg Med Chem Lett 26:4362-6 (2016) [PubMed]  Article 
Target
Name:
MAP/microtubule affinity-regulating kinase 3
Synonyms:
2.7.11.1 | C-TAK1 | CTAK1 | Cdc25C-associated protein kinase 1 | ELKL motif kinase 2 | EMK-2 | EMK2 | MAP/microtubule affinity-regulating kinase 3 | MAP/microtubule affinity-regulating kinase 3 (MARK 3) | MARK3 | MARK3_HUMAN | Par-1a | Protein kinase STK10 | Ser/Thr protein kinase PAR-1 | Serine/threonine-protein kinase c-TAK1 | Serine/threonine-protein kinase p78
Type:
Protein
Mol. Mass.:
84525.94
Organism:
Homo sapiens (Human)
Description:
P27448
Residue:
753
Sequence:
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKTQLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLKAENLLLDADMNIKIADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDASDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVSSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGKGIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRIRFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRRNMSFRFIKRLPTEYERNGRYEGSSRNVSAEQKDENKEAKPRSLRFTWSMKTTSSMDPGDMMREIRKVLDANNCDYEQRERFLLFCVHGDGHAENLVQWEMEVCKLPRLSLNGVRFKRISGTSIAFKNIASKIANELKL
  
Inhibitor
Name:
BDBM50536675
Synonyms:
CHEMBL4569508
Type:
Small organic molecule
Emp. Form.:
C26H26F3N5O2S
Mol. Mass.:
529.577
SMILES:
FC(F)(F)CNC(=O)c1cc(cs1)-c1cnn2cc(cnc12)-c1ccc(OCCN2CCCCC2)cc1
Structure:
Search PDB for entries with ligand similarity: